Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Pharmasset (NASDAQ:VRUS) gained $6.25 (45%) to $20.24 on Monday after preliminary data from
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury